Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

Promega's Cookie Policy

We use cookies and similar technologies to make our website work, run analytics, improve our website, and show you personalized content and advertising. Some of these cookies are essential for our website to work. For others, we won’t set them unless you accept them. To find out more about cookies and how to manage cookies, read our Cookie Policy.

Expanding Applications of Bioluminescence Technology Predictive Bioassays for TNFa Biologicals Potency and Dose-Standardization Studies

Sarah Shultz, Andrew Niles, Jey Cheng and Simon T.M. Allard
Promega Corporation
Publication Date: 2008

Abstract

Simple and predictive bioassays for potency and dose-standardization are still sought by the biopharmaceutical industry. Automatable, homogeneous bioassays are desirable because they can help to streamline this evaluative process. Implementing straightforward predictive automation-friendly bioassays as demonstrated in this article allows effective assessment of anti-TNFa and likely other biologicals for quality control. This article was reprinted in Promega Notes 100 with permission from Genetic Engineering News.

Promega Notes 100, 19–21.